ACRO’s new RBQM Summary Report, authored by the ACRO RBQM Working Group, highlights key takeaways from the past three years of ACRO’s RBM/RBQM landscape survey of 5,000+ ongoing clinical trials.
The Summary Report focuses on the most significant findings from the past three years of survey data, providing a snapshot of the progress in RBM/RBQM adoption from 2019 – 2021, including adoption rates of remote monitoring, QTLs, centralized monitoring, and several other components.
Read the full report on ACRO’s website.
ACRO members are invited to download and share this statement and we encourage colleagues, customers, and other stakeholders to do the same.